| Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African … H Takahashi, GR Wilkinson, EA Nutescu, T Morita, MD Ritchie, ... Pharmacogenetics and genomics 16 (2), 101-110, 2006 | 478 | 2006 |
| Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance MG Scordo, V Pengo, E Spina, ML Dahl, M Gusella, R Padrini Clinical Pharmacology & Therapeutics 72 (6), 702-710, 2002 | 460 | 2002 |
| A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor L Gallinaro, MG Cattini, M Sztukowska, R Padrini, F Sartorello, E Pontara, ... Blood, The Journal of the American Society of Hematology 111 (7), 3540-3545, 2008 | 327 | 2008 |
| Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers P Palatini, L Tedeschi, G Frison, R Padrini, R Zordan, R Orlando, ... European journal of clinical pharmacology 45, 353-356, 1993 | 319 | 1993 |
| Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis R Orlando, M Mussap, M Plebani, P Piccoli, S De Martin, M Floreani, ... Clinical chemistry 48 (6), 850-858, 2002 | 209 | 2002 |
| Reduced von Willebrand factor survival in type Vicenza von Willebrand disease A Casonato, E Pontara, F Sartorello, MG Cattini, MT Sartori, R Padrini, ... Blood, The Journal of the American Society of Hematology 99 (1), 180-184, 2002 | 191 | 2002 |
| A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy AK Hamberg, ML Dahl, M Barban, MG Scordo, M Wadelius, V Pengo, ... Clinical Pharmacology & Therapeutics 81 (4), 529-538, 2007 | 180 | 2007 |
| Severe phenytoin intoxication in a subject homozygous for CYP2C9*3 R Brandolese, MG Scordo, E Spina, M Gusella, R Padrini Clinical Pharmacology & Therapeutics 70 (4), 391-394, 2001 | 155 | 2001 |
| Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer M Gusella, AC Frigo, C Bolzonella, R Marinelli, C Barile, A Bononi, ... British journal of cancer 100 (10), 1549-1557, 2009 | 132 | 2009 |
| Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function R Orlando, P Piccoli, S De Martin, R Padrini, M Floreani, P Palatini Clinical Pharmacology & Therapeutics 75 (1), 80-88, 2004 | 128 | 2004 |
| A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age AK Hamberg, M Wadelius, JD Lindh, ML Dahl, R Padrini, P Deloukas, ... Clinical Pharmacology & Therapeutics 87 (6), 727-734, 2010 | 122 | 2010 |
| Relationships between body composition parameters and fluorouracil pharmacokinetics M Gusella, S Toso, E Ferrazzi, M Ferrari, R Padrini British journal of clinical pharmacology 54 (2), 131-139, 2002 | 99 | 2002 |
| Phthalates and heavy metals as endocrine disruptors in food: a study on pre-packed coffee products L De Toni, F Tisato, R Seraglia, M Roverso, V Gandin, C Marzano, ... Toxicology reports 4, 234-239, 2017 | 85 | 2017 |
| Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. R Orlando, M Floreani, R Padrini, P Palatini Clinical nephrology 51 (6), 341-347, 1999 | 85 | 1999 |
| On the mechanism of vasodilating action of berberine: possible role of inositol lipid signaling system. S Bova, R Padrini, WF Goldman, DM Berman, G Cargnelli Journal of Pharmacology and Experimental Therapeutics 261 (1), 318-323, 1992 | 83 | 1992 |
| VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study CF Zambon, V Pengo, R Padrini, D Basso, S Schiavon, P Fogar, A Nisi, ... Pharmacogenomics 12 (1), 15-25, 2011 | 81 | 2011 |
| Clinical pharmacokinetics and pharmacodynamics of direct oral anticoagulants in patients with renal failure R Padrini European journal of drug metabolism and pharmacokinetics 44 (1), 1-12, 2019 | 79 | 2019 |
| Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer … S Afzal, M Gusella, B Vainer, UB Vogel, JT Andersen, K Broedbaek, ... Clinical Cancer Research 17 (11), 3822-3829, 2011 | 74 | 2011 |
| Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function R Orlando, P Piccoli, S De Martin, R Padrini, P Palatini British journal of clinical pharmacology 55 (1), 86-93, 2003 | 71 | 2003 |
| Effect of moderate or severe liver dysfunction on the pharmacokinetics of γ-hydroxybutyric acid SD Ferrara, L Tedeschi, G Frison, R Orlando, M Mazzo, R Zordan, ... European journal of clinical pharmacology 50, 305-310, 1996 | 66 | 1996 |
